SciSparc Ltd. (SPRC) 宣布,其持股75%的子公司Neurothera Labs已正式签署最终协议,将收购Cliniquantum的多数股权。Cliniquantum是一家专注于量子计算技术应用于临床实验领域的创新公司。此次收购标志着SciSparc在推进创新疗法和临床开发平台方面迈出重要一步。
SciSparc Ltd. (SPRC) 宣布,其持股75%的子公司Neurothera Labs已正式签署最终协议,将收购Cliniquantum的多数股权。Cliniquantum是一家专注于量子计算技术应用于临床实验领域的创新公司。此次收购标志着SciSparc在推进创新疗法和临床开发平台方面迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.